GlaxoSmithKline (GSK) Price & Analysis

Compare

1,079 Followers

GSK Stock Chart & Stats

1620.00p

-0.50p(-0.04%)

At close: Jan 09 4:00 PM EST

1620.00p

-0.50p(-0.04%)

Day’s Range― - ―

52-Week Range1,242.50p - 1,684.50p

Previous CloseN/A

Volume367.08K

Average Volume (3M)8.54M

Market Cap

£65.11B

Enterprise Value73.93B

Total Cash (Recent Filing)£3.62B

Total Debt (Recent Filing)£17.35B

Price to Earnings (P/E)19.3

Beta0.85

Next Earnings

Oct 29, 2025

EPS Estimate

0.47

Last Dividend Ex-Date

Aug 14, 2025

Dividend Yield3.62%

Share Statistics

EPS (TTM)0.45

Shares Outstanding4,062,590,600

10 Day Avg. Volume6,837,178

30 Day Avg. Volume8,542,213

Financial Highlights & Ratios

PEG Ratio-0.44

Price to Book (P/B)4.02

Price to Sales (P/S)1.75

P/FCF Ratio15.37

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£1,589.92

Price Target Upside-1.86% Downside

Rating ConsensusHold

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Leadership ChangeNew CEO appointment is likely to shift sentiment positively relative to analyst's Underperform thesis.

Market Opportunity3L+ setting is seen as a significant opportunity for Blenrep given the new mechanism of action.

Regulatory ApprovalFDA approval of Blenrep in relapsed refractory multiple myeloma is seen as a positive outcome following the negative ODAC decision.

Bears Say

Financial PerformanceDespite being one of the lowest P/E stocks in the sector, GSK has the worst expected EPS growth rate from 2027 to 2030.

Product CompetitionMixed physician feedback and building competition from JNJ's Tecvayli could limit the commercial opportunity for Blenrep.

Regulatory ConstraintsApproval is restricted to 3L+ only, despite seeking approval for 2L+, which further narrows the potential patient population.

GlaxoSmithKline News

GSK assumed with a Buy at Jefferies

Jefferies assumed coverage of GSK (GSK) with a Buy rating and 2,000 GBp price target At a 30%...

2h ago

GSK

GSK acquires exclusive rights from Syndivia for ADC in prostate cancer

GSK (GSK) announced an agreement granting GSK exclusive worldwide rights to develop and commercialise a preclinical ADC for...

2h ago

GSK

GSK’s Blenrep approved by FDA for treatment of relapsed multiple myeloma

GSK (GSK) announced the U.S. Food and Drug Administration (FDA) has approved Blenrep in combination with bortezomib and...

4d ago

GSK

Trump Trade: Trump administration prepares new probe into pharma prices

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

5d ago

AZN

GSK announces Phase III data from program to develop Ventolin

GSK (GSK) announced positive phase III data from its clinical program to develop a next-generation version of its...

5d ago

GSK

Trump admin prepares new probe into U.S. pharma prices, FT says

President Donald Trump’s administration is preparing a new probe into U.S. trading partners over drug pricing, Aime Williams...

5d ago

AZN

GSK announce EMA CHMP issued positive opinion for Shingrix in prefilled syringe

GSK (GSK) announced that the European Medicine Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has...

6d ago

GSK

Spero Therapeutics, GSK announce PIVOT-PO trial efficacy and safety results

Spero Therapeutics (SPRO) and GSK plc (GSK) announced efficacy and safety results of the phase 3 PIVOT-PO trial...

6d ago

GSK

SPRO

GSK treatment of malignant glioma designated for FDA orphan status

GSK’s (GSK) niraparib was granted FDA orphan designation as a treatment of malignant glioma, according to a post...

10d ago

GSK

ViiV Healthcare announces 96-week data from PASO DOBLE on Dovato

ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Pfizer (PFE) and Shionogi as...

10d ago

GSK

PFE

GSK Advances Share Buyback Program with Latest Purchase

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has announced the purchase of 555,000 of...

6h ago

Sell Rating for GlaxoSmithKline Due to Limited Growth Prospects for Blenrep Amid Competitive Challenges and Regulatory Hurdles

Sarita Kapila, an analyst from Morgan Stanley, maintained the Sell rating on GlaxoSmithKline. The associated price target is...

3d ago

GSK

Sell Rating Issued for GlaxoSmithKline’s Blenrep Due to Restrictive Approval and Market Limitations

Bank of America Securities analyst Sachin Jain has maintained their bearish stance on GSK stock, giving a Sell...

3d ago

GSK

GSK Advances Share Buyback Program with Recent Purchase

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has announced the purchase of 366,000 of its own...

3d ago

GSK FAQ

What was GlaxoSmithKline’s price range in the past 12 months?

GlaxoSmithKline lowest share price was 1242.50p and its highest was 1684.50p in the past 12 months.

What is GlaxoSmithKline’s market cap?

GlaxoSmithKline’s market cap is £65.11B.

When is GlaxoSmithKline’s upcoming earnings report date?

GlaxoSmithKline’s upcoming earnings report date is Oct 29, 2025 which is in 2 days.

How were GlaxoSmithKline’s earnings last quarter?

GlaxoSmithKline released its earnings results on Apr 30, 2025. The company reported 0.449p earnings per share for the quarter, beating the consensus estimate of 0.4p by 0.049p.

Is GlaxoSmithKline overvalued?

According to Wall Street analysts GlaxoSmithKline’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does GlaxoSmithKline pay dividends?

GlaxoSmithKline pays a Quarterly dividend of 16p which represents an annual dividend yield of 3.62%. See more information on GlaxoSmithKline dividends here

What is GlaxoSmithKline’s EPS estimate?

GlaxoSmithKline’s EPS estimate is 0.47.

How many shares outstanding does GlaxoSmithKline have?

GlaxoSmithKline has 4,062,590,600 shares outstanding.

What happened to GlaxoSmithKline’s price movement after its last earnings report?

GlaxoSmithKline reported an EPS of 0.449p in its last earnings report, beating expectations of 0.4p. Following the earnings report the stock price went up 3.597%.

Which hedge fund is a major shareholder of GlaxoSmithKline?

Currently, no hedge funds are holding shares in GB:GSK

GlaxoSmithKline Stock Smart Score

Neutral

Fundamentals

Return on Equity

23.47%

Trailing 12-Months

Asset Growth

2.05%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

GlaxoSmithKline

GlaxoSmithKline (GSK) is a global healthcare company headquartered in Brentford, United Kingdom. It operates in three main sectors: Pharmaceuticals, Vaccines, and Consumer Healthcare. GSK develops and manufactures a wide range of products, including innovative medicines for respiratory, HIV, and oncology conditions, vaccines for diseases such as influenza and shingles, and consumer healthcare products like oral health, pain relief, and wellness solutions.

GlaxoSmithKline (GSK) Earnings & Revenues

Historic Earnings Reports

GSK Stock 12 Month Forecast

Average Price Target

1,589.92p

▼(-1.86% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1295":"1,295p","1514":"1,514p","1733":"1,733p","1952":"1,952p","2171":"2,171p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1589.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.59K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1345,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.34K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1295,1514,1733,1952,2171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1671.5,1709.8461538461538,1748.1923076923076,1786.5384615384614,1824.8846153846155,1863.2307692307693,1901.576923076923,1939.923076923077,1978.2692307692307,2016.6153846153848,2054.9615384615386,2093.3076923076924,2131.653846153846,{"y":2170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1671.5,1665.2246153846154,1658.9492307692308,1652.6738461538462,1646.3984615384616,1640.123076923077,1633.8476923076923,1627.5723076923077,1621.2969230769231,1615.0215384615385,1608.746153846154,1602.4707692307693,1596.1953846153847,{"y":1589.92,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1671.5,1646.3846153846155,1621.2692307692307,1596.1538461538462,1571.0384615384614,1545.923076923077,1520.8076923076924,1495.6923076923076,1470.576923076923,1445.4615384615386,1420.3461538461538,1395.2307692307693,1370.1153846153845,{"y":1345,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1454.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1356.61,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1296.34,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1301.18,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1357.71,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1433.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1435.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1429.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1500.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1396.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1380.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1447.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1671.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >